Vascular News and Research

RSS

Thoratec commences CE Mark Clinical Trial for HeartMate III chronic left ventricular assist system

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that its CE Mark Clinical Trial for HeartMate III™ commenced with the first patient implanted with this new device.

27 Jun 2014

OSNP program addresses potential gaps in outpatient settings

An innovative framework for identifying and addressing potential gaps in health care in outpatient settings using electronic clinical surveillance tools has been used to target patient safety across a variety of conditions, according to a study published today in the journal eGEMs.

26 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.

25 Jun 2014

Functional status informs blood pressure risks in elderly

The functional status of elderly people modifies the association between their blood pressure and cardiovascular disease risk, a study shows.

23 Jun 2014

New driver of atherosclerosis may prove to be promising therapeutic target

A new driver of atherosclerosis has been identified by researchers at UT Southwestern Medical Center. This molecule, known as 27HC (27-hydroxycholesterol), has been found to exacerbate the development of the condition, and may prove to be a promising therapeutic target.

20 Jun 2014

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

20 Jun 2014

Researchers discover crucial process that regulates development of blood vessels

Biologists at The Scripps Research Institute (TSRI) have discovered a crucial process that regulates the development of blood vessels.

19 Jun 2014

NDC announces voluntary recall of HydroFinity Hydrophilic Guidewires

Nitinol Devices & Components, Inc. announced today a voluntary recall of its HydroFinity Hydrophilic Guidewires. The HydroFinity Guidewire is a product developed and manufactured by NDC and distributed by Covidien.

18 Jun 2014

La Jolla Institute researchers advance work toward vaccine for heart disease

Research toward the world's first vaccine for heart disease continues to advance at the La Jolla Institute for Allergy and Immunology, with researchers demonstrating significant arterial plaque reduction in concept testing in mice.

18 Jun 2014

Outpatient diabetes care quality matters after limb revascularisation

High quality outpatient diabetes care improves diabetic patients’ chances of avoiding major ischaemic events and amputation after undergoing limb revascularisation, a study shows.

16 Jun 2014

New partnership in kidney transplantation provides most advanced patient care to Lubbock

UT Southwestern Medical Center and the University Medical Center Health System (UMC) in Lubbock, Texas, have forged a new partnership in kidney transplantation that provides the most advanced patient care, while enabling patients to prepare for and recover from surgery close to home.

16 Jun 2014

Study supports proposal to screen all men with gout for presence of ED

A new study presented today at the European League Against Rheumatism Annual Congress showed that erectile dysfunction (ED) is present in most men with gout and is frequently severe.

12 Jun 2014

Aston University plans for new Medical School to train new generation of doctors

Aston University (UK) has announced plans for a new Medical School which will train a new generation of doctors in Birmingham and the West Midlands.

12 Jun 2014

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

12 Jun 2014

Pulsar Vascular announces FDA approval of PulseRider IDE for intracranial bifurcation aneurysms

Pulsar Vascular, the innovator and developer of the PulseRider, a minimally invasive, aneurysm neck reconstruction device, announced today the United States Food and Drug Administration's approval of an Investigational Device Exemption (IDE) for the PulseRider.

10 Jun 2014

BP history affects late-life brain pathology

The relationship between late-life blood pressure and damage to the brain is modified by midlife hypertension history, research shows.

9 Jun 2014

Prevalence of pulmonary arterial hypertension characterised in CHD patients

Pulmonary arterial hypertension affects just over 3% of individuals with congenital heart disease, reveal nationwide data from the Netherlands.

6 Jun 2014

Cardiac biomarkers aid microvascular risk prediction in diabetics

Assessing cardiac biomarkers results in a moderate improvement in the ability to predict microvascular complications in patients with Type 2 diabetes, say researchers.

6 Jun 2014

Lombard Medical showcases Aorfix Endovascular Stent Graft at SVS Annual Meeting

Lombard Medical, Inc., a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAA), showcased its Aorfix Endovascular Stent Graft at the 2014 Society for Vascular Surgery Annual Meeting in Boston, June 5-7.

6 Jun 2014